Improving drug development for diverse populations
Official title: 1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
Funded at Beckman Research Institute/city of Hope · NIH-10933458 · Data updated 2026-11-12
This study is working to make sure that new medicines are safe and effective for everyone, especially African Americans and Latinos, by training a diverse group of researchers and improving how drugs are developed.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $1,311,431 |
| NIH project number | 5U54CA285116-02 |
| Project ID | NIH-10933458 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are African American and Latino individuals who may be affected by conditions like breast cancer.
✕Less likely to help
Patients who are not part of the African American or Latino communities may not receive direct benefits from this research.
What this research studies
This research focuses on addressing disparities in drug development by ensuring that drugs are tested and optimized for diverse populations, particularly African Americans and Latinos. The project aims to build resources, infrastructure, and training programs to mentor a new generation of researchers who reflect the diversity of the communities they serve. By enhancing collaboration between institutions, the research seeks to reduce the inequities present in the drug discovery pipeline, ensuring that new medications are safe and effective for all populations.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective medications for diverse populations, reducing health disparities.
How similar studies have gone: Other research has shown success in addressing health disparities through community engagement and diverse clinical trial participation, making this approach promising.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Seewaldt, Victoria L. — Beckman Research Institute/city of Hope
- Study coordinator: Seewaldt, Victoria L.
Related research
Other NIH-funded projects on the same topics.
-
Targeting the protein-assembly that drives AML growth
Aiming to slow or stop acute myeloid leukemia by blocking how cancer cells make proteins.
-
Metformin for reversing accelerated aging in young adults with metabolic health issues
A practical plan to use metformin to help 18- to 35-year-olds with insulin resistance improve metabolic health and slow aging.
-
PIN1-targeted therapy for pancreatic cancer
A team is developing new PIN1 inhibitors to treat pancreatic cancer that tends to resist current therapies.
-
DNA mismatch repair defects and anti-tumor immunity in cancer
Researchers are studying how defects in a DNA repair system affect the body’s immune response to tumors, to improve cancer treatments that use the immune system.
-
Understanding how skin cancer-associated fibroblasts affect immune detection in early mycosis fungoides
This grant investigates how certain skin cells in early mycosis fungoides might help the cancer hide from the immune system, with findings aiming to improve future patient care.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.